panitumumab
The KRAS inhibitor, which recorded $77 million in sales during the quarter, improved progression-free survival when combined with Vectibix in colorectal cancer patients.
In ComboMatch, the successor to NCI-MATCH, researchers will evaluate drug combos that try to inhibit genomic drivers of cancer and stave off resistance.
Amgen's Q1 Revenues Fall 2 Percent Amid Precision Oncology Sales Growth
The drugmaker saw 41 percent growth in sales of Blincyto and 19 percent growth in sales of Lumakras driven by multiple clinical trial readouts.
However, in the Phase III PARADIGM trial, there was no difference in survival between the two arms when researchers focused only on patients with right-sided tumors.
Ligand Expression Predicts Vectibix Benefit in Colon Cancer, Roche and U of Leeds Study Says
An artificial intelligence- and IHC-based assay predicted improved benefit with Amgen's panitumumab among patients with high AREG and EREG ligand expression.